¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£© H5AY6),  
_e 3'f:  
  Ò»¡¢Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© E)P1`X  
  1¡¢Co-stimulators (or co-stimulating molecules) 8if"U xV(  
  2¡¢NK-kB f+6l0@K2  
  3¡¢Immunoglobulin superfamily Ae#6=]V+^  
  4¡¢antigen-presenting cell (APC) =gIYa  
  5¡¢death domain -AT@M1K7%  
  6¡¢CCR and CXCR rYJ ))@  
  7¡¢Lectin (or mitogen) ]G B},  
  8¡¢Clusters of differentiation, CD) "!tB";n  
  9¡¢B7 family 1I`D$Xq~:  
  10¡¢Cytotoxic T lymphocyte, CTL) 4.'EEuRw\}  
  11¡¢IL-15 and IL-15 receptor (IL-15R) D$cMPFa2Nt  
  12¡¢MHC restriction =;H'~  
  13¡¢Affinity-chromatography mTfMuPPs[  
  14¡¢Cyctosprin A, CsA Bkc-iC}F  
  15¡¢Antibody-dependent cell-mediated cytotoxicity, ADCC) )9r%% #  
dx}/#jMa  
  ¶þ¡¢¼ò´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© @:&+wq_>A^  
  1¡¢ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 4AYc 8Z#'  
  2¡¢ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ F4x7;?W{*  
  3¡¢ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ib_Gy77Os  
^wa9zs2s;/  
  Èý¡¢ÎÊ´ðÌ⣨25·Ö£© wIF ":'  
  1¡¢Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 7]%il[  
  ѪҺ²¡Ñ§×¨Òµ£º 4E>(Y98  
  2¡¢ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»